Virtual Library

Start Your Search

Samuel Bernal



Author of

  • +

    P3.09 - Pathology (Not CME Accredited Session) (ID 975)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.09-01 - PDL1 Profile of Filipino Lung Adenocarcinoma Patients Show Moderate Positivity and Low EGFR Correlation (ID 14348)

      12:00 - 13:30  |  Author(s): Samuel Bernal

      • Abstract
      • Slides

      Background

      The recent approval of anti-PD1 or PDL1 immunotherapy based on promising clinical trial results ushers in the accelerated adoption of pertinent companion diagnostics to make available the relevant therapy to cancer patients. The Lung Center of the Philippines established a routine immunohistochemistry-based diagnostic for PDL1 in collaboration with pharmaceutical companies to address the existing gap in diagnostic information that may have therapeutic implications in terms of who and to what extent, this subset of population may benefit from this new targeted therapy. This study aims to report the PDL1 profile of Filipino lung adenocarcinoma patients and evaluate its possible correlation with EGFR mutation.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Tumor block samples from 345 Filipino lung adenocarcinoma patients were processed for PDL1 testing using the Ventana PDL1 Assay. Samples with positive results were subjected to Cobas EGFR mutation testing.

      4c3880bb027f159e801041b1021e88e8 Result

      One hundred forty-two samples (i.e., 41.2%) were positive for the PDL1 markers. Majority of samples tested were males (i.e., 62-65% males vs. 35-38% females) with ages ranging from 64-66 years for both males and females. From a subset of eleven PDL1 positive samples, only three showed positive EGFR mutations (i.e., 27.3%) with two, showing L858R mutation and one T790M mutation.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Moderate presence of the PDL1 markers were shown by Filipino lung adenocarcinoma patients suggesting that a moderate population could potentially benefit from anti-PD1 or PDL1 immunotherapy. Meanwhile, the low presence of EGFR mutation detected from the subset of PDL1 positive samples suggest a possibly mutually exclusive pattern for these biomarkers consistent with those reported in other studies. Albeit preliminary, co-EGFR testing could provide rationalization of clinical response and an alternative therapeutic targeting for this subset of patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.